Worldwide Clinical Trials Brings Together Bioanalytical and Cardiovascular Expertise for your Dyslipidemia Study

Dyslipidemia refers to an unhealthy level of lipids in the blood and has been related to cardiovascular diseases.

Although lipid-modifying therapies have been shown to mitigate risks of cardiovascular disease, these medications do carry some risks. Thus, the goal for further dyslipidemia research is to develop safer and more effective lipid-modifying interventions.

The ideal CRO partner for your dyslipidemia study will be able to bring together research expertise in both hematology and cardiovascular conditions within an infrastructure that can take on the bioanalytical challenges of these projects.

Whether you need study design support, clinical investigation services, or full project management, Worldwide Clinical Trials is up for the task. Our background in cardiovascular indications includes collaboration on cardiovascular and cardiometabolic research with a number of academic research organizations, and we have a history in cardiovascular research, with hundreds of thousands of patients in thousands of sites globally.

Our bioanalytical labs are equipped with state-of-the-art instrumentation and run by highly trained staff. With Worldwide as your partner, you can be assured of our commitment to your trial, and that includes a study team dedicated specifically to your study to ensure that we meet your requirements to the letter.